Data Show Cymbalta Improved Functioning of Patients With Diabetic Neuropathy
Cymbalta significantly improved physical, social and emotional functioning, in addition to overall health, in patients with pain associated with diabetic peripheral neuropathy (DPNP), compared with those treated with a sugar pill, according to a pooled analysis of three studies.
In the pooled analysis of more than 1,000 DPNP patients, those treated with 60 or 120 mg of Cymbalta (duloxetine HCl), given as 60 mg either once or twice daily, reported significant improvements in all functional components defined in three commonly used scales - the interference portion of the Brief Pain Inventory (BPI), the Short Form 36 (SF-36) and the European Quality of Life Instrument 5D version (EQ-5D).
That means Cymbalta patients reported significantly less interference from pain on key measures of physical functioning, including their ability to walk, work and sleep. On a social level, patients taking Cymbalta reported significantly less interference from pain on their relationships with other people and their enjoyment of life. Additionally, Cymbalta patients reported significantly less interference from pain on mental health and mood.
Upcoming Events
-
21Oct